In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation

mAbs

Volumn 6, Issue 2, 2014, Pages 437-445

  Li, Bing ^a   Fouts, Ashley E ^a   Stengel, Katharina ^a   Luan, Peng ^a   Dillon, Michael ^a   Liang, Wei Ching ^a   Feierbach, Becket ^a   Kelley, Robert F ^a   Hötzel, Isidro ^a  

^a GENENTECH INC   (United States)

Author keywords

Affinity; Antibody; Codon; Cytomegalovirus; Glycosylation; Maturation; Mutagenesis; Neutralization

Indexed keywords

AMINO ACID; ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY AFFINITY; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; CODON USAGE; CONTROLLED STUDY; ESCHERICHIA COLI; FIBROBLAST; GLYCOSYLATION; HEAVY CHAIN; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; MATURATION; MUTATION; NONHUMAN; PHAGE DISPLAY; PROTEIN EXPRESSION; VIRUS NEUTRALIZATION;

AFFINITY; ANTIBODY; CODON; CYTOMEGALOVIRUS; GLYCOSYLATION; MATURATION; MUTAGENESIS; NEUTRALIZATION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CELL SURFACE DISPLAY TECHNIQUES; CHO CELLS; CRICETULUS; CYTOMEGALOVIRUS; DNA MUTATIONAL ANALYSIS; GLYCOSYLATION; HUMANS; MUTAGENESIS; MUTATION; TRANSGENES;

EID: 84896516865     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27875     Document Type: Article

References (19)

1. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74; PMID:20811384; http://dx.doi.org/10.1038/nrd3229
2. Poulsen TR, Meijer PJ, Jensen A, Nielsen LS, Andersen PS. Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J Immunol 2007; 179:3841-50; PMID:17785821
3. Poulsen TR, Jensen A, Haurum JS, Andersen PS. Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. J Immunol 2011; 187:4229-35; PMID:21930965; http://dx.doi.org/10.4049/jimmunol. 1000928
4. Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A 1995; 92:1254-6; PMID:7877964; http://dx.doi.org/10.1073/pnas.92.5.1254
5. Batista FD, Neuberger MS. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 1998; 8:751-9; PMID:9655489; http://dx.doi.org/10.1016/S1074-7613(00)80580-4
6. Kauffman SA, Weinberger ED. The NK model of rugged fitness landscapes and its application to maturation of the immune response. J Theor Biol 1989; 141:211-45; PMID:2632988; http://dx.doi.org/10.1016/S0022-5193(89)80019-0
7. Macken CA, Perelson AS. Protein evolution on rugged landscapes. Proc Natl Acad Sci U S A 1989; 86:6191-5; PMID:2762321; http://dx.doi.org/10.1073/pnas. 86.16.6191
8. Voigt CA, Kauffman S, Wang ZG. Rational evolutionary design: the theory of in vitro protein evolution. Adv Protein Chem 2000; 55:79-160; PMID:11050933
9. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368:652-65; PMID:17362988; http://dx.doi.org/10.1016/j.jmb.2007.02.024
10. Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4:753-60; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
11. Whitehead TA, Chevalier A, Song Y, Dreyfus C, Fleishman SJ, De Mattos C, Myers CA, Kamisetty H, Blair P, Wilson IA, et al. Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol 2012; 30:543-8; PMID:22634563; http://dx.doi.org/10.1038/nbt. 2214
12. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 2004; 340:1073-93; PMID:15236968; http://dx.doi.org/10.1016/j.jmb.2004.05.051
13. Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol 2004; 338:299-310; PMID:15066433; http://dx.doi.org/10.1016/j.jmb. 2004.02.050
14. Sidhu SS, Lowman HB, Cunningham BC, Wells JA. Phage display for selection of novel binding peptides. Methods Enzymol 2000; 328:333-63; PMID:11075354; http://dx.doi.org/10.1016/S0076-6879(00)28406-1
15. Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. [xiii.]. Methods Mol Biol 2009; 525:353-76, xiii; PMID:19252851; http://dx.doi.org/10.1007/978-1-59745-554-1-19
16. Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C. Construction and characterization of an active factor VIII variant lacking the central onethird of the molecule. Biochemistry 1986; 25:8343-7; PMID:3030393; http://dx.doi.org/10.1021/bi00374a001
17. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263:133-47; PMID:12009210; http://dx.doi.org/10.1016/S0022-1759(02)00036-4
18. Grazia Revello M, Baldanti F, Percivalle E, Sarasini A, De-Giuli L, Genini E, Lilleri D, Labò N, Gerna G. In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 2001; 82:1429-38; PMID:11369888
19. Abai AM, Smith LR, Wloch MK. Novel microneutralization assay for HCMV using automated data collection and analysis. J Immunol Methods 2007; 322:82-93; PMID:17343873; http://dx.doi.org/10.1016/j.jim.2007.02.001